By Fineline Cube 
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in China, a Category 1 drug approved in December last year for treating early symptomatic Alzheimer’s disease (AD). This includes adults with mild cognitive impairment (MCI) and mild dementia stage AD.
Therapy Details
Kisunla is administered as a once-monthly intravenous (IV) infusion. It stands out as the only amyloid plaque-targeting therapy that allows for discontinuation once plaques are cleared, potentially reducing treatment costs and minimizing the number of infusions required.
Clinical Efficacy
Clinical studies have demonstrated that Kisunla significantly slows disease progression, with a 35% reduction in patients with early disease stages and a 22% reduction overall. The therapy has also been shown to reduce the risk of progression to moderate dementia by 50%, helping patients maintain independence for up to 37.3 months longer.-Fineline Info & Tech